Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Horm Metab Res ; 54(8): 567-570, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35636457

RESUMEN

The Covid-19 pandemic has provided new and strong evidence for poor outcomes of viral infection in patients with poor metabolic health. Insulin resistance is at the root of many metabolic conditions and a key driver of their progression as it promotes ineffectual inflammation whilst impairing immune functions. In a vicious circle, insulin resistance facilitates SARS-CoV-2 infection, whilst infection drives insulin resistance. We discuss the underlying mechanisms and explore ways to improve metabolic health and prevent insulin resistance through early detection and targeted nutritional interventions. With proven efficacy in prediabetes, type 2 diabetes, and their cardiovascular and organ complications, as much as non-alcoholic liver disease, we argue to extend such approaches to ensure resilience to the current pandemic and viral challenges beyond.


Asunto(s)
COVID-19 , Diabetes Mellitus Tipo 2 , Resistencia a la Insulina , COVID-19/complicaciones , Diabetes Mellitus Tipo 2/complicaciones , Diabetes Mellitus Tipo 2/terapia , Humanos , Sistema Inmunológico , Pandemias , Conducta de Reducción del Riesgo , SARS-CoV-2 , Síndrome Post Agudo de COVID-19
2.
Horm Metab Res ; 53(8): 529-540, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34192792

RESUMEN

Insulin resistance is the hallmark of Type 2 Diabetes and is still an unmet medical need. Insulin resistance lies at the crossroads of non-alcoholic fatty liver disease, obesity, weight loss and exercise resistance, heart disease, stroke, depression, and brain health. Insulin resistance is purely nutrition related, with a typical molecular disease food intake pattern. The insulin resistant state is accessible by TyG as the appropriate surrogate marker, which is found to lead the personalized molecular hepatic nutrition system for highly efficient insulin resistance remission. Treating insulin resistance with a molecular nutrition-centered approach shifts the treatment paradigm of Type 2 Diabetes from management to cure. This allows remission within five months, with a high efficiency rate of 85%. With molecular intermittent fasting a very efficient treatment for prediabetes and metabolic syndrome is possible, improving the non-alcoholic fatty liver disease (NAFL) state and enabling the body to lose weight in a sustainable manner.


Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Ayuno/metabolismo , Resistencia a la Insulina , Hígado/metabolismo , Síndrome Metabólico/metabolismo , Adulto , Anciano , Anciano de 80 o más Años , Índice de Masa Corporal , HDL-Colesterol/sangre , Diabetes Mellitus Tipo 2/terapia , Dieta , Femenino , Humanos , Masculino , Síndrome Metabólico/terapia , Persona de Mediana Edad , Estado Prediabético/metabolismo , Estado Prediabético/terapia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...